New Muscular Dystrophy Drug Granted FDA Orphan Designation in US
BB-301's potential
Meaning, that once fully approved and on the market, the original orphan drug and the technology behind it could significantly help the company's bottom line. A company with a strong bottom line, especially a pharmaceutical company, will be in the position to develop more treatment options and drugs, which will ultimately help more people.
